RussianPatents.com

Photochemical internalisation for molecule transportation to cytosol. RU patent 2333246.

FIELD: chemistry.

SUBSTANCE: invention concerns molecular biology and can be applied in medicine. One variant of molecule introduction into a cell cytosol involves contact of transported molecule to the cell after its incubation with photosensitiser and irradiation. The other variant of the method involves contact of transported molecule to the cell after its incubation with photosensitiser either during or after irradiation. Methods of disease, disorder or infection treatment or prevention, gene therapy, cancer treatment and immune response stimulation are developed on the basis of this method. Transport cell of therapeutically tolerable molecule and a cell presenting antigen molecule are also obtained by the said method.

EFFECT: reduced level of photochemical damage of transported molecule and possibility of wide variability of the transported molecule introduction time relative to photosensitiser-containing cell irradiation time.

53 cl, 26 dwg, 1 tbl, 24 ex

IPC classes for russian patent Photochemical internalisation for molecule transportation to cytosol. RU patent 2333246. (RU 2333246):

C12N15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

A61K48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

A61K41 - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J0003000000; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L)

A61K39 - Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N0033530000)

Another patents in same IPC classes:

Compound / 2323940
Photosensitising agents obtained by reducing a double bond in porphyrinic macrocycle of sulphonated mesotetraphenylporphyrine, preferably disulphonated mesotetraphenylporphyrine, such as TPPS2a. Resulting sulphonated mesotetraphenylchlorines are compounds of formula (I) , (where X stands for -SO3Н; each of n, p, q and r independently stands for 0 or 1; and sum of n, p, q and r is an integer from 1 to 4, preferably at least 2, in particular, 2 or 4), isomers or isomeric mixture. Compounds in accordance with the said invention and pharmaceutically suitable salts thereof have a high extinction coefficient in the region of 630 to 680 nm.

Small rna molecules mediating rna interference / 2322500
Invention proposes RNA molecule able to target-specific interference of RNA and represents a double-stranded RNA molecule of size 19-22 nucleotides and having 3'-bulge consisting of 1-5 nucleotides This RNA is prepared by combining two chains of RNA and used for preparing a pharmaceutical composition. After incorporation into the multicellular eucaryotic organism this RNA molecule provides promotion to target-specific interference of RNA and results to decreasing level of expression of the gene-target or to knockout of the gene-target. Method for promotion of target-specific interference of RNA using this RNA molecule is used in assay and modulation of gene function. Cell containing endogenous nucleic acid-target, RNA molecule able for target-specific RNA interference and exogenous nucleic acid-target is used in analytical procedures. Using the invention provides silence of the gene-target mediated by target-specific interference of RNA.

Molecular complex for transfection of mammalian cells, containing plasmide dna, modified polyethyleneimine, and ligand molecules / 2303064
Disclosed is molecular transfecting complex (MTC) comprising of plasmide DNA carrying necessary genetic information, polyethyleneimine, modifies with acylhydrazine groups and being capable to form ion complexes with plasmide DNA, ligand molecules for receptor-mediated MTC addressing to certain cell types and providing prolonged MTC circulation in blood. Ligand molecule contains one or more aldehyde groups, whereby such molecules may be attached after DNA-acylhydrazidopolyethyleneimine complex formation. Invention is useful in medicine for gene therapy.

Method for in vivo transformation of animal testicle stem cells / 2290442
Claimed method includes injection of vector construct pX-RSVhGH encoding human growth hormone or pX-Ins, encoding human insulin into parenchyma of 8-9-week rabbit males. Transformation effectiveness of gene constructs is determined by immunohystochemical kit Novocastra (Sigma, USA).

Method for analysis of analytes with the use of particles as marks / 2251572
The invention is dealt with a method of detection and measurement of one or more analytes for analysis in a sample. The method provides for binding of one or more analytes for analysis in a sample with light-diffusing particles; illumination of any of such particles bound with the analytes by a light under conditions, which allow to have a diffuse light from the particles and at which the light diffused from one or more particles can be detected by a human eye at magnification of no less than in 500 times and without an electronic amplifier. In the capacity of a measure for detecting of presence of such analytes the method also provides for detection of the light diffused by any of such particles under certain conditions.

Active angiogenesis-preventing immunetherapy / 2329824
Invention refers to medicine and concerns angiogenesis-preventing immunotherapy. Invention substance includes immunogenic compositions for treatment of disorders associated with angiogenesis intensification, containing oligonucleotides, coding polypeptides VEGFR2, introduced as a part of plasmid or viral vectors, as well as polypeptides VEGFR2, oligonucleotides, coding autologous VEGF with damaged function of receptor activation, polypeptides VEGF and their combinations. Immunogenic compositions can be used for treatment of malignant neoplasms and metastasises, at benign neoplasm and chronic inflammatory and autoimmune diseases. Advantage of invention lies in humoral and cellular immunity induction by means of specified compositions.

Dna sequence and production of grass pollen allergen phi p4 using reconbinant methods / 2327739
Provides genetic sequence of grass pollen main allergen Phi p 4. Fragments of this sequence, combinations of its partial sequences and point mutants have hypoallergenic action. Recombinant molecules of DNA and derivative polypeptides, fragments, new combination of partial sequences and versions can be applied for treatment of diseases associated with grass pollen allergy.

Method for treating diseases / 2322264
Method involves introducing fragmented DNA into patient organism. The DNA is allogenic. It is received from genetically and physiologically healthy donors and has fragments which length corresponds to 1-10 units of nucleosomes making up full patient genome in association with nucleus matrix proteins. Fragmented DNA is introduced in the amount that enables one to achieve fragmented DNA concentration in patient blood plasma equal to or greater than the own patient blood plasma DNA concentration but not greater than 1500 ng/l.

Preparation, recombinant plasmid dna psx70 encoding synthesis of human recombinant granulocyte-colony-stimulating factor (g-csf), escherichia coli sx70 strain as producer of human recombinant g-csf and method for industrial preparing g-csf / 2321424
Invention relates to methods for industrial preparing the human recombinant granulocyte-colony-stimulating factor (G-CSF) of medicinal designation, and to recombinant Escherichia coli (E. coli) strains and plasmids used for its preparing. Group of inventions involves creature of recombinant plasmid DNA pSX70, constructing recombinant industrial Escherichia coli pSX70 strain-producer deposited in All-Russian collection of Industrial Microorganisms (VKPM), FGUP Gos. NII Genetics at collection number VKPM B-8842. Invention provides preparing G-CSF with the high yield by relatively simple and safety technology that can be used as a base for preparing composition in form of aqueous solution for injection.

Dna vaccine against proliferating endothelial cells and uses thereof / 2318019
Claimed vaccine includes DNA construct operatively encoding receptor protein of vessel endothelial growth factor (VEGF) selected from group containing VEGFR-2 (KDR; SEQ ID NO:2), VEGFR-1 (Flt-1; SEQ ID NO:4) or Flk-1 (mice KDR homologue, SEQ ID NO:6) and functional equivalent thereof having of about 80 % homology. Encoding receptor proteins of DNA-sequence are represented in SEQ ID NO: 1, 2 and 5, and in description. Described are methods for uses of DNA-vaccines as inhibitors of proliferating endothelial cells in mammalian by administering of DNA-vaccine to stimulate of immune response in relation to proliferating endothelial cells, in particular to inhibit angiogenesis and tumor growth. Also disclosed is dosage form of DNA-vaccine.

Photochemical internalization method for carrying out virus-mediated molecule delivery into cytozole / 2317827
Method involves introducing nucleic acid into a cell through said cell interaction with photosensitizing agent and nucleic acid molecule to be introduced. The molecule is a part virus carrier genome or one transferred as virus carrier component. The cell is irradiated with light of wavelength effective for activating the photosensitizing agent.

Neusserial vaccine compositions containing combination of antigens / 2317106
Invention relates to immune compositions and vaccines used in treatment and prophylaxis of neusserial disease. Immune compositions comprise combinations of antigens chosen from at least two different classes of antigens and comprising adhesions, auto-transporting proteins, toxins, proteins taking part in assimilation of iron and membrane-associated proteins (preferably integral protein(s) of external membrane). Such combinations of antigens are able to target the immune response against different aspects of Neusseria vital cycle that results to the more effective immune response.

Method for introducing therapeutic viruses / 2314830
Method involves introducing one or more desensitizing virus doses in turn in single cycle, followed by introducing one or more greater doses of virus. The virus is a negative filiform RNA virus. Virus quantity available in the second and any following desensitizing dose is to be greater than virus quantity in the preceding desensitizing dose. Virus quantity available in each of one or more increased doses is to be higher than virus quantity in each desensitizing dose.

Modulation of expression of stat-1-depended genes / 2311456
Invention proposes double-stranded DNA-oligonucleotides (trap-oligonucleotides) binding transcription factor STAT-1 specifically and neutralizing its effect in cell. Size of trap-oligonucleotides is from 15 to 21 pair nucleotides, and they are characterized by a sequence that comprises 2 sites for binding the STAT-1 protein. Invention shows possibilities in using novel DNA-oligonucleotides as a medicinal agent for prophylaxis and/or therapy of immune hypersensitivity responses.

Method for treatment of pregnant women with undifferentiated dysplasia of connecting tissue / 2333018
Physiotherapy with a running impulsive magnetic field of low frequency is performed. Manipulation is performed with 1.5 mT power of magnetic induction and 100 Hz frequency of following impulses. The method involves influencing paravertebrally on the level CVII-ThV with didymous solenoids of N-S polarity. The procedure lasts for 15 minutes within 7-10 days. The method also includes carring out intravenous injection of Riboxinum once a day and intaking infusion of hawthorn foetuses 3 times a day within 10 days.

Method for treatment of cervical radiculo- and/or myelophatic syndromes of spondilo- and/or discogenic type / 2333017
Spinal cord decompression by the closed method or with opening the spinal canal is performed. Startins from the first day after operation, electrophoresis is carried out to continue for 15-22 days. Within the first 1-3 days, it is performed using neuroprotective preparations, or with biogenic stimulators, then, within 10-14 days, with glucocorticoid, after that, with antispasmodics. From the 3-4 days, an electrical stimulation is carried out to for 10-14 days. The method further includes carring out an electrical stimulation of trunks of a humeral plexus in supraclavicular area and on a course of the amazed root in the field of a forearm. And, if spinal cord decompression is carried out with opening the spinal channel, the course of an electrophoresis and an electrical stimulation in the postoperative period is performed twice, at closed decompression being performed once.

Tinting hairspray / 2332984
Tinting hairspray includes a film-forming substance, dissolvent, vitamin complex (VC), fragrance component, propellent or preservative, and, additionally ethyl acetate, and, as a vitamin complex (VC), Solutio oleosa of crystalline β-carotin that is preliminary extracted from a biomass of Blakeslea trispora mushroom, washed out in ethyl alcohol for excision of the remnants from the biomass, then the cleared crystals are dissolved in deodorised, refined sunflower, corn or olive oils.

Mousse for styling damaged hair / 2332983
Mousse for styling damaged hair includes quaternised cationic polymer, wedding agent PEG-40 of hydrogenised castor oil, a modified corn starch, fragrance component, preservative, vitamin complex, UV-propellent and demineralised water. Additionally, it contains emulgents Cremophore A6 and Cremophore A25, and, as a vitamin complex, Solutio oleosa of crystalline β-carotin. The vitamin complex (VC) in the form of Solutio oleosa of crystalline β-carotin, contains β-carotin extracted from a biomass of mushroom Blakeslea trispora by washing with ethyl alcohol for excision of the remnants from the biomass, with the subsequent dissolution of the cleared crystals in deodorised, refined sunflower, corn or olive oils.

Method of organism purification (variants) / 2332980
Invention is available in two variants. For this purpose, in the first variant, in addition to a saltless vegetarian diet with reception, priorto a meal, of cholagogue collectings, cappiring out a liver/gall bladder cleanse/flush at the 4th day together with honey-juice diet, performance of enema treatment of intestine with broths of grasses at the 1st, 3nd and 3rd days after a dinner and two enema treatments after a breakfast at the 5th day and stomach massage at the 2nd, 3rd and 4th days of a course of purification, the method also involves carrying out thermal procedures in the form of a sauna or a bath at the 1st, 3rd and 5th days of a course of purification, and, additionally, a Charcot's douche every other day are alternated with a circular shower. In the second variant of the method, a Charcot's douche or a circular shower every other day are alternated with mineral baths.

Method of aftertreatment of children and teenagers with autoimmune thyroiditis in combination with chronic pharyngotonsillitis / 2332978
Method involves carrying out balneotherapy, foing physiotherapy exercises and intaking iodomarine and/or L-tiroksin. In first half of the day, physiotherapy exercises are performed, general artificial radon baths being performed in the second half of the day. Manual massages of a collar zone are perform in days free from baths. From November till March phonophoresis of Traumel S ointment on a thyroid gland projection is also performed with an intensity of 0.05 W/cm2, continuous regimen, duration of influence of 3-5 minutes on the right and at the left, general time of influence of 6-10 minutes, in a day with a magnetotherapy on a projection of palatine tonsils, size of a magnetic induction being 6-9 mT, for 5-6 minutes from each party, general time of 10-12 minutes, in a course of 8-10 procedures. At treatment during the period from April till October, patients are additionally prescribed a group galotherapy in the second half of the day, in a course of 10-15 procedures, and phototherapy of red range at a wavelength of 660-675 nanometers, densities of power of radiation of 1 mW/cm2 and an infra-red range at a wavelength of 840-950 nanometers, densities of power of radiation of 2.7 mW/cm2 to biologically active points: VC-20, VC-22, E-36 symmetrically on the right and the left, Gi-4 symmetrically on the right and the left. Time of influence for one point is 1.5-2 minutes, general time of influence being 9-12 minutes, daily, in 10-12 procedures, with duration of treatment making up 21-24 days.